Essex Bio-Technology Ltd
01061
Company Profile
Business description
Essex Bio-Technology Ltd is principally engaged in investment holding and development, manufacture and sale of biologic drugs in the People’s Republic of China. The company is made up of segments of Ophthalmology products and Surgical products. Its products under Ophthalmology include the Beifushu series, Tobramycin Eye Drops, Levofloxacin Eye Drops, Sodium Hyaluronate Eye Drops. The products under Surgical include the Beifuji series, Carisolv dental caries removal gel and mouth wash. The majority of the groups revenue comes from PRC.
Contact
No. 88, Keji 6th Road
Hi-Tech Zone
Guangdong
Zhuhai
CHNT: +86 7563911188
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
1,426
Stocks News & Analysis
stocks
Procter & Gamble earnings: Frigid sales and margins don’t suggest cracks in its standing
North America was a notable blemish, down 2% on an organic basis.
stocks
Our view on Santos after production is ramped up
Barossa at 75% capacity and Pikka undergoing commissioning.
stocks
GE Aerospace earnings: No good deed goes unpunished
We’ve raised our fair value estimate of GE Aerospace stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,189.90 | 15.70 | 0.17% |
| CAC 40 | 8,137.00 | 11.89 | -0.15% |
| DAX 40 | 24,862.82 | 6.35 | 0.03% |
| Dow JONES (US) | 49,384.01 | 306.78 | 0.63% |
| FTSE 100 | 10,166.99 | 16.94 | 0.17% |
| HKSE | 26,749.51 | 119.55 | 0.45% |
| NASDAQ | 23,436.02 | 211.20 | 0.91% |
| Nikkei 225 | 53,846.87 | 157.98 | 0.29% |
| NZX 50 Index | 13,448.24 | 108.63 | -0.80% |
| S&P 500 | 6,913.35 | 37.73 | 0.55% |
| S&P/ASX 200 | 8,860.10 | 15.00 | 0.17% |
| SSE Composite Index | 4,136.16 | 13.59 | 0.33% |